CLINICAL RESEARCH: HEART FAILURE
Dynamic Cardiovascular Risk Assessment in Elderly PeopleThe Role of Repeated N-Terminal Pro–B-Type Natriuretic Peptide Testing
Christopher R. deFilippi, MD*,*,
Robert H. Christenson, PhD ,
John S. Gottdiener, MD*,
Willem J. Kop, PhD* and
Stephen L. Seliger, MD, MS
* Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland
Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland
Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland
Manuscript received March 3, 2009;
revised manuscript received June 3, 2009,
accepted July 6, 2009.
* Reprint requests and correspondence: Dr. Christopher R. deFilippi, G3K63, Division of Cardiology, University of Maryland, 22 South Greene Street, Baltimore, Maryland 21201 (Email: cdefilip{at}medicine.umaryland.edu).
Objectives: This study sought to determine whether serial measurement of N-terminal pro–B-type natriuretic peptide (NT-proBNP) in community-dwelling elderly people would provide additional prognostic information to that from traditional risk factors.
Background: Accurate cardiovascular risk stratification is challenging in elderly people.
Methods: NT-proBNP was measured at baseline and 2 to 3 years later in 2,975 community-dwelling older adults free of heart failure in the longitudinal CHS (Cardiovascular Health Study). This investigation examined the risk of new-onset heart failure (HF) and death from cardiovascular causes associated with baseline NT-proBNP and changes in NT-proBNP levels, adjusting for potential confounders.
Results: NT-proBNP levels in the highest quintile (>267.7 pg/ml) were independently associated with greater risks of HF (hazard ratio [HR]: 3.05; 95% confidence interval [CI]: 2.46 to 3.78) and cardiovascular death (HR: 3.02; 95% CI: 2.36 to 3.86) compared with the lowest quintile (<47.5 pg/ml). The inflection point for elevated risk occurred at NT-proBNP 190 pg/ml. Among participants with initially low NT-proBNP (<190 pg/ml), those who developed a >25% increase on follow-up to >190 pg/ml (21%) were at greater adjusted risk of HF (HR: 2.13; 95% CI: 1.68 to 2.71) and cardiovascular death (HR: 1.91; 95% CI: 1.43 to 2.53) compared with those with sustained low levels. Among participants with initially high NT-proBNP, those who developed a >25% increase (40%) were at higher risk of HF (HR: 2.06; 95% CI: 1.56 to 2.72) and cardiovascular death (HR: 1.88; 95% CI: 1.37 to 2.57), whereas those who developed a >25% decrease to 190 pg/ml (15%) were at lower risk of HF (HR: 0.58; 95% CI: 0.36 to 0.93) and cardiovascular death (HR: 0.57; 95% CI: 0.32 to 1.01) compared with those with unchanged high values.
Conclusions: NT-proBNP levels independently predict heart failure and cardiovascular death in older adults. NT-proBNP levels frequently change over time, and these fluctuations reflect dynamic changes in cardiovascular risk.
Key Words: biomarkers risk stratification heart failure elderly
|
Abbreviations and Acronyms
| | CI = confidence interval | | ECG = electrocardiogram | | HF = heart failure | | LV = left ventricle/ventricular | | LVEF = left ventricular ejection fraction | | NT-proBNP = N-terminal pro–B-type natriuretic peptide | | ROC = receiver-operator characteristic |
|
Related Articles
-
Improving Risk Stratification for Heart Failure: A Role for Serial Testing of B-Type Natriuretic Peptides?
- Matthew G. Daly, Christopher M. Frampton, and Richard W. Troughton
J. Am. Coll. Cardiol. 2010 55: 451-453.
[Full Text]
[PDF]
-
Inside This Issue
J. Am. Coll. Cardiol. 2010 55: A32.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
C. R. deFilippi, R. H. Christenson, W. J. Kop, J. S. Gottdiener, M. Zhan, and S. L. Seliger
Left Ventricular Ejection Fraction Assessment in Older Adults: An Adjunct to Natriuretic Peptide Testing to Identify Risk of New-Onset Heart Failure and Cardiovascular Death?
J. Am. Coll. Cardiol.,
September 27, 2011;
58(14):
1497 - 1506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. T. RUFF, D. A. MORROW, P. JAROLIM, F. REN, C. F. CONTANT, A. KAUR, S. P. CURTIS, L. LAINE, C. P. CANNON, and K. BRUNE
Evaluation of NT-proBNP and High Sensitivity C-Reactive Protein for Predicting Cardiovascular Risk in Patients with Arthritis Taking Longterm Nonsteroidal Antiinflammatory Drugs
J Rheumatol,
June 1, 2011;
38(6):
1071 - 1078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y. W. Lew, J. A. C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2010
J. Am. Coll. Cardiol.,
January 25, 2011;
57(4):
480 - 514.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. deFilippi, J. A. de Lemos, R. H. Christenson, J. S. Gottdiener, W. J. Kop, M. Zhan, and S. L. Seliger
Association of Serial Measures of Cardiac Troponin T Using a Sensitive Assay With Incident Heart Failure and Cardiovascular Mortality in Older Adults
JAMA,
December 8, 2010;
304(22):
2494 - 2502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G. Daly, C. M. Frampton, and R. W. Troughton
Improving Risk Stratification for Heart Failure: A Role for Serial Testing of B-Type Natriuretic Peptides?
J. Am. Coll. Cardiol.,
February 2, 2010;
55(5):
451 - 453.
[Full Text]
[PDF]
|
 |
|
|